PTEN and cancer: Gain of function mutations in constituents of this pathway, amplification of PIK3CA and AKT, overexpression of AKT and inactivating mutations or loss of PTEN are involved in the aberrant activity of this signaling pathway and subsequent progression of cancer {Simpson, 2015 #155}.